# UroGen Pharma

Type: Company (URGN)

Source: GetYourBrief — https://getyourbrief.com/entity/urogen-pharma
Canonical HTML page: https://getyourbrief.com/entity/urogen-pharma

## Recent coverage (4 stories, network-wide)

### MEC’s Data Center Revenue Rockets 173% as AI Buildout Fuels Demand
2026-08-08 22:30:49 · Sector: proptech · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Mayville Engineering’s Q2 results reveal a staggering 173% organic growth in data center and critical power revenue, underscoring the property-tech sector's long-term structural tailwind from artificial intelligence. With a pipeline exceeding $125 million, MEC is a bellwether for the construction boom in digital infrastructure.
Full story: https://getproptechbrief.com/story/mayville-engineering-data-center-surge-q2-2026

### Alto Ingredients' Crush Margin Triples, Drives 4th Profitable Quarter
2026-08-08 22:30:36 · Sector: climate · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Biofuel producer Alto Ingredients posted its fourth straight profitable quarter as crush margins expanded to $0.33 per gallon from $0.11 a year ago and 45Z tax credits kicked in. The results demonstrate how federal low-carbon fuel policy is strengthening the ethanol business case.
Full story: https://getclimatebrief.com/story/alto-ingredients-profitability-renewable-fuel-credits-q2-2026

### Urogen's ZUSDURI Revenue Soars 73% to $50.4M, Expanding Prescriber Base
2026-08-08 22:30:23 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Urogen Pharma’s bladder cancer therapy ZUSDURI generated $50.4M in Q2 net product revenue, a 73% sequential jump, as the company activated 1,444 accounts and doubled repeat prescribers. The strong commercial launch highlights robust demand in biotech’s niche oncology space.
Full story: https://getbiobrief.com/story/urogen-pharma-zusduri-revenue-surge-q2-2026

### UroGen and Senseonics Lead MedTech Growth as Commercial Transitions Take Hold
2026-03-03 00:21:55 · Sector: bio · Sentiment: Neutral · Impact: 6/10 · Sources: 11

UroGen Pharma and Senseonics reported strong Q4 2025 results, driven by the successful commercial launches of Zasturi and Eversense 365. Both companies are navigating critical transitions—UroGen through new reimbursement codes and Senseonics by assuming full commercial control—positioning them for significant revenue scaling in 2026.
Full story: https://getbiobrief.com/story/urogen-senseonics-q4-2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.